Mounjaro — what is it, and what does it actually do?

What the trial data showed before it reached UK pharmacies

Mounjaro's licence in the UK rests primarily on the SURMOUNT programme, a series of trials conducted before the medicine was approved here. SURMOUNT-1 randomised 2,539 adults with obesity (none had type 2 diabetes) and tracked them for 72 weeks. At the 15 mg dose, average body-weight reduction was around 20–21%, a figure that the original SURMOUNT-1 paper, published in the New England Journal of Medicine, described as substantially larger than what had been seen with single-receptor treatments in comparable studies. A subsequent head-to-head trial, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks and found tirzepatide produced greater average weight loss.

NICE reviewed this evidence and in December 2024 recommended tirzepatide for NHS use in adults with a BMI of 35 or above and at least one weight-related condition, thresholds that are 2.5 kg/m² lower for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. That recommendation covers specific NHS cohorts being phased in over time; private treatment through a regulated pharmacy follows the licensed criteria in the medicine's SmPC, which your prescriber applies to your individual circumstances.

Numbers mean more in context. An average 20% reduction at the highest dose translates to 20 kg lost for someone starting at 100 kg, but averages include people who lost more and people who lost less. Clinical trials are the cleanest evidence available, and they are the reason the medicine was licensed; they are not a personal prediction.

How tirzepatide works, the dual-receptor mechanism

If you want a fuller background on the medicine itself, our page explaining what tirzepatide is and how it fits into the treatment landscape covers that in detail. It binds to both the GLP-1 receptor and the GIP receptor, two pathways involved in appetite signalling and the body's response to food. GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite and influences insulin release. GIP (glucose-dependent insulinotropic polypeptide) has overlapping and complementary effects on energy regulation. Activating both together appears to produce a larger appetite-suppressing effect than either pathway alone, which is the leading explanation researchers give for the trial results.

You can read more about how the GIP pathway specifically contributes on our page covering what GIP does in Mounjaro. The short version: it is not simply a stronger version of an existing drug. It is a structurally different approach, which is why tirzepatide sits in its own category rather than alongside the GLP-1-only medicines that preceded it.

Practically, what patients tend to notice is a reduction in hunger and a much earlier sense of fullness after eating. Gastric emptying slows, so food stays in the stomach longer. Some people also notice changes in food cravings. If you are interested in the specific ingredients and formulation behind those effects, our page on what tirzepatide is made of breaks that down clearly. None of this happens overnight; the 2.5 mg starter dose is there to let the body adjust, and the prescriber titrates upward based on tolerance and response.

What Mounjaro is licensed for, and who can be assessed for it privately

In the UK, Mounjaro holds two licences: weight management in adults, and type 2 diabetes. The weight-management licence applies to adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. The NHS medicines page for tirzepatide sets out the medicine's profile in plain terms.

Age is a firm limit: the licence covers adults only, and Mounjaro is not prescribed for anyone under 18. Pregnancy, breastfeeding and trying to conceive are contraindications; women of childbearing age should discuss contraception with their prescriber, since tirzepatide can affect absorption of oral contraceptive pills during the first four weeks of treatment and after each dose increase. A non-oral method is recommended alongside the pill during those windows.

A BMI figure alone does not determine whether treatment is right for you, the prescriber looks at the full picture, including other medicines you take and any conditions in your history. If you are curious about how age factors into eligibility, that page covers the specifics. For a broader look at what the treatment involves and what else is available, our weight-loss treatment overview is a good starting point.

Side effects, monitoring and what to watch for

The most commonly reported side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, reflux and burping. These tend to be most noticeable when starting or moving up a dose, and they often settle within a week or two as the body adjusts. Headache, fatigue and injection-site reactions are also reported.

One serious but infrequent side effect worth knowing about is acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically highlighting this risk. The warning sign to act on is severe, persistent stomach pain that may radiate through to the back, with or without vomiting, that combination warrants urgent medical attention, not a wait-and-see approach.

Because Mounjaro carries Black Triangle (▼) status, any suspected side effect can and should be reported via the MHRA's Yellow Card scheme. This is how post-market safety monitoring works in the UK, and patient reports genuinely feed into it. Patients on Mounjaro should also mention it to any healthcare professional they see, including dentists and surgeons, since the medicine has implications for anaesthesia and for other medicines taken orally.

Pricing is a separate question that comes up frequently, if cost is part of your thinking, our page on Mounjaro costs in the UK covers what market pricing looks like and what to include in any comparison.